Last reviewed · How we verify
Continuous Release Dopamine Agonists
Continuous release dopamine agonists stimulate dopamine receptors in the brain to provide sustained therapeutic effects for movement and neurological disorders.
Continuous release dopamine agonists stimulate dopamine receptors in the brain to provide sustained therapeutic effects for movement and neurological disorders. Used for Parkinson's disease, Restless legs syndrome.
At a glance
| Generic name | Continuous Release Dopamine Agonists |
|---|---|
| Also known as | ropinirole extended release |
| Sponsor | University of Toledo |
| Drug class | Dopamine agonist |
| Target | Dopamine receptors (D1, D2, D3, D4, D5) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Dopamine agonists work by directly binding to and activating dopamine receptors (D1, D2, or other subtypes) in the central nervous system. The continuous release formulation maintains steady-state dopamine receptor stimulation over extended periods, reducing dosing frequency and improving symptom control compared to immediate-release formulations. This approach is particularly useful in conditions where dopamine deficiency or dysfunction contributes to motor and non-motor symptoms.
Approved indications
- Parkinson's disease
- Restless legs syndrome
Common side effects
- Nausea
- Dizziness
- Somnolence
- Hallucinations
- Orthostatic hypotension
- Impulse control disorders
Key clinical trials
- Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU (PHASE3)
- Impact of Switching to Continuous Release Dopamine Agonists (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Continuous Release Dopamine Agonists CI brief — competitive landscape report
- Continuous Release Dopamine Agonists updates RSS · CI watch RSS
- University of Toledo portfolio CI